+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Sorrento Therapeutics Expands Resiniferatoxin Rtx Clinical Development Program To Life Threatening Cardiovascular Diseases With Completion Of Major Animal Toxicology Study is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release Sorrento Therapeutics Expands Resiniferatoxin Rtx Clinical Development Program To Life Threatening Cardiovascular Diseases With Completion Of Major Animal Toxicology Study | RobinsPost News & Noticias

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study


Neumora is advancing pre-clinical safety and toxicology ... of life for patients suffering from brain diseases. Cautionary Note Regarding Forward-Looking Statements This press release contains forward ... Read More

Nurix Therapeutics Announces Proposed Public Offering


SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics ... clinical development of its drug candidates, to fund research and development activities to expand its pipeline and for working ... Read More

Forbes Press Releases


In this section, you’ll find the latest Forbes press releases and news announcements. The collective net worth of Korea’s 50 Richest on the 2024 Forbes list rose slightly to US$115 billion ... Read More

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735


Notes: Safety population, includes all randomized subjects who received at least one dose of study ... Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development ... Read More

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)


We believe that our leadership in developing drugs for muscular diseases and promising ... Further information on the OBA program and the clinical study is expected to be provided through the coming ... Read More

Canadians Without Life Threatening Diseases Are Being Encouraged to Consider Suicide | Opinion


As of this year, the MAID program was also set to allow those with mental illness to choose euthanasia. However, a recent development on ... yet the choice to end life is a permanent one. Read More

PRESS RELEASE: CITY OF BLOOMINGTON’S LEADERSHIP IN SUSTAINABILITY EXPANDS RENEWABLE ENERGY PRODUCTION ACROSS THE COMMUNITY IN 2023


The following is a press release written by Angela Van Rooy for City of Bloomington ... In 2023, the Solar, Energy Efficiency, and Lighting Program (SEEL) provided $25,000 grants to ten nonprofit ... Read More

Law Firm Newswire Expands Press Release Distribution Plan Giving Lawyers Access to The Street and MSN for Less


This move will offer law firms a more comprehensive network, reaching over 450 websites and other major broadcasting channels at a rate that competes with mainstream press release wires. Read More

Bray Wyatt Reportedly Near WWE Return After ‘Life-Threatening’ Illness


WWE could soon get a major star power boost in the form of ... Inc), Wyatt is nearing a triumphant return after battling a “life-threatening” illness: “ Wyatt is inching closer to being ... Read More

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study


Neumora is advancing pre-clinical safety and toxicology ... diseases. We anticipate several important milestones including Phase 3 data in major depressive disorder and the initiation of a Phase 2 ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus